GeneNews offers ColonSentry®, a new patient friendly blood test for colorectal cancer. ColonSentry® has the potential to save thousands of lives and can serve as the first step in the early identification of colorectal cancer. The test assesses your current risk of having colorectal cancer and provides additional information to help you and your doctor make important decisions on next steps regarding your colon health.
ColonSentry is based on award-winning technology, powered by the Sentinel Principle®, which uses a blood sample to identify telltale RNA biomarkers for early disease.
Benefits of ColonSentry®:
- A simple blood test
- Patient friendly
- Minimal risk of complications
- No dietary restrictions
- No handling of stool or toilet water
ColonSentry® helps prioritize patients for screening colonoscopy by providing a current risk assessment. ColonSentry® is currently available in Canada, USA, Malaysia and China.
For more information about ColonSentry®, please visit the website at: www.colonsentry.com